Brendon L Neuen1, Toshiaki Ohkuma1, Bruce Neal1, David R Matthews2, Dick de Zeeuw3, Kenneth W Mahaffey4, Greg Fulcher5, Jaime Blais6, Qiang Li1, Meg J Jardine7, Vlado Perkovic8, David C Wheeler9. 1. The George Institute for Global Health, UNSW Sydney, Sydney, Australia. 2. Oxford Centre for Diabetes, Endocrinology and Metabolism and Harris Manchester College, University of Oxford, Oxford, United Kingdom. 3. Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands. 4. Royal North Shore Hospital, Sydney, Australia. 5. Stanford Center for Clinical Research, Department of Medicine, Stanford University School of Medicine, Stanford, CA. 6. Janssen Scientific Affairs, LLC, Titusville, NJ. 7. The George Institute for Global Health, UNSW Sydney, Sydney, Australia; Concord Repatriation General Hospital, Sydney, Australia. 8. The George Institute for Global Health, UNSW Sydney, Sydney, Australia; Janssen Scientific Affairs, LLC, Titusville, NJ. 9. The George Institute for Global Health, UNSW Sydney, Sydney, Australia; Centre for Nephrology, University College London, London, United Kingdom. Electronic address: d.wheeler@ucl.ac.uk.
Abstract
RATIONALE & OBJECTIVE:Canagliflozin reduces the risk for cardiovascular and kidney outcomes in type 2 diabetes. This study aimed to assess the relative and absolute effects of canagliflozin on clinical outcomes across different KDIGO (Kidney Disease: Improving Global Outcomes) risk categories based on estimated glomerular filtration rate (eGFR) and urinary albumin-creatinine ratio. STUDY DESIGN: Post hoc analysis of the CANagliflozin cardioVascular Assessment Study (CANVAS) Program. SETTINGS & PARTICIPANTS: The CANVAS Program randomly assigned 10,142 participants with type 2 diabetes at high cardiovascular risk and with eGFR≥30mL/min/1.73m2 to treatment withcanagliflozin or placebo. INTERVENTION(S): Canagliflozin or matching placebo. OUTCOMES: The primary outcome was a composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke, with a set of other cardiovascular and kidney prespecified outcomes. RESULTS: Of 10,142 participants, 10,031 (98.9%) had available baseline eGFR and urinary albumin-creatinine ratio data. The proportion of participants in low-, moderate-, high-, and very high-risk KDIGO categories was 58.6%, 25.8%, 10.6%, and 5.0%, respectively. The relative effect of canagliflozin on the primary outcome (HR, 0.86; 95% CI, 0.75-0.97) was consistent across KDIGO risk categories (P trend=0.2), with similar results for other cardiovascular and kidney outcomes. Absolute reductions in the primary outcome were greater within higher KDIGO risk categories (P trend=0.03) with a similar pattern of effect for the composite of cardiovascular death or hospitalization for heart failure (P trend=0.06) and for chronic eGFR slope (P trend = 0.04). LIMITATIONS: Predominantly a low kidney risk population, relatively few participants in higher KDIGO risk categories, and exclusion of individuals with eGFR<30mL/min/1.73m2. CONCLUSIONS: Although the relative effects of canagliflozin are similar across KDIGO risk categories, absolute risk reductions are likely greater for individuals at higher KDIGO risk. The KDIGO classification system may be able to identify individuals who might derive greater benefits for end-organ protection from treatment with canagliflozin. FUNDING: This post hoc analysis was not specifically funded. The original CANVAS Program trials were funded by Janssen Research & Development, LLC and were conducted as a collaboration between the funder, an academic steering committee, and an academic research organization, George Clinical. TRIAL REGISTRATION: The original trials of the CANVAS Program were registered at ClinicalTrials.gov with study numbers NCT01032629 and NCT01989754.
RCT Entities:
RATIONALE & OBJECTIVE:Canagliflozin reduces the risk for cardiovascular and kidney outcomes in type 2 diabetes. This study aimed to assess the relative and absolute effects of canagliflozin on clinical outcomes across different KDIGO (Kidney Disease: Improving Global Outcomes) risk categories based on estimated glomerular filtration rate (eGFR) and urinary albumin-creatinine ratio. STUDY DESIGN: Post hoc analysis of the CANagliflozin cardioVascular Assessment Study (CANVAS) Program. SETTINGS & PARTICIPANTS: The CANVAS Program randomly assigned 10,142 participants with type 2 diabetes at high cardiovascular risk and with eGFR≥30mL/min/1.73m2 to treatment with canagliflozin or placebo. INTERVENTION(S): Canagliflozin or matching placebo. OUTCOMES: The primary outcome was a composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke, with a set of other cardiovascular and kidney prespecified outcomes. RESULTS: Of 10,142 participants, 10,031 (98.9%) had available baseline eGFR and urinary albumin-creatinine ratio data. The proportion of participants in low-, moderate-, high-, and very high-risk KDIGO categories was 58.6%, 25.8%, 10.6%, and 5.0%, respectively. The relative effect of canagliflozin on the primary outcome (HR, 0.86; 95% CI, 0.75-0.97) was consistent across KDIGO risk categories (P trend=0.2), with similar results for other cardiovascular and kidney outcomes. Absolute reductions in the primary outcome were greater within higher KDIGO risk categories (P trend=0.03) with a similar pattern of effect for the composite of cardiovascular death or hospitalization for heart failure (P trend=0.06) and for chronic eGFR slope (P trend = 0.04). LIMITATIONS: Predominantly a low kidney risk population, relatively few participants in higher KDIGO risk categories, and exclusion of individuals with eGFR<30mL/min/1.73m2. CONCLUSIONS: Although the relative effects of canagliflozin are similar across KDIGO risk categories, absolute risk reductions are likely greater for individuals at higher KDIGO risk. The KDIGO classification system may be able to identify individuals who might derive greater benefits for end-organ protection from treatment with canagliflozin. FUNDING: This post hoc analysis was not specifically funded. The original CANVAS Program trials were funded by Janssen Research & Development, LLC and were conducted as a collaboration between the funder, an academic steering committee, and an academic research organization, George Clinical. TRIAL REGISTRATION: The original trials of the CANVAS Program were registered at ClinicalTrials.gov with study numbers NCT01032629 and NCT01989754.
Authors: Girish N Nadkarni; Dipti Takale; Bruce Neal; Kenneth W Mahaffey; Yshai Yavin; Michael K Hansen; Fergus Fleming; Hiddo J L Heerspink; Steven G Coca Journal: Kidney360 Date: 2022-05-18
Authors: David M Charytan; Jie Yu; Meg J Jardine; Christopher P Cannon; Rajiv Agarwal; George Bakris; Tom Greene; Adeera Levin; Carol Pollock; Neil R Powe; Clare Arnott; Kenneth W Mahaffey Journal: Clin J Am Soc Nephrol Date: 2022-01-21 Impact factor: 8.237
Authors: Simke W Waijer; Priya Vart; David Z I Cherney; Glenn M Chertow; Niels Jongs; Anna Maria Langkilde; Johannes F E Mann; Ofri Mosenzon; John J V McMurray; Peter Rossing; Ricardo Correa-Rotter; Bergur V Stefansson; Robert D Toto; David C Wheeler; Hiddo J L Heerspink Journal: Diabetologia Date: 2022-04-21 Impact factor: 10.460
Authors: Natalie Staplin; Alistair J Roddick; Jonathan Emberson; Christina Reith; Alex Riding; Alexa Wonnacott; Apexa Kuverji; Sunil Bhandari; Colin Baigent; Richard Haynes; William G Herrington Journal: EClinicalMedicine Date: 2021-10-26
Authors: John P H Wilding; Marc Evans; Kevin Fernando; Jose Luis Gorriz; Ana Cebrian; Jane Diggle; Debbie Hicks; June James; Philip Newland-Jones; Amar Ali; Stephen Bain; Andrea Da Porto; Dipesh Patel; Adie Viljoen; David C Wheeler; Stefano Del Prato Journal: Diabetes Ther Date: 2022-03-20 Impact factor: 3.595